Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02450591 · ClinicalTrials.gov registry record · NA
Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations
A NA study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 4
- Enrollment target
NCT02450591: Completed NA study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02450591 is a NA study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 4 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02450591, a NA study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
Study Summary
This study will test if local therapies in addition to erlotinib can improve responses and delay the time until new treatment is required. This study will also collect blood samples for research blood tests.
Primary Outcome
At least five patients will need to complete local therapy within 2 years of the study being open to accrual for the primary endpoint to be met.
Interventions
- DRUG Erlotinib
- OTHER Local Therapies
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2015-05-14 |
| Est. Completion | 2017-12-11 |
| Phase | NA |
What the finished NCT02450591 record still lists
NCT02450591 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which Erlotinib is the first listed.
NCT02450591 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02450591 about?
NCT02450591 is a clinical study titled "Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations". This study will test if local therapies in addition to erlotinib can improve responses and delay the time until new treatment is required. This study will also collect blood samples for research blood tests.
What is the current status of trial NCT02450591?
This trial is currently completed. It is a NA study. The enrollment target is 4 participants. The study started on 2015-05-14. Estimated completion is 2017-12-11.
What interventions are being tested in trial NCT02450591?
The interventions under investigation include: Erlotinib (DRUG), Local Therapies (OTHER).
Who is sponsoring clinical trial NCT02450591?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02450591's enrollment target sits among peer trials
4 1996th of 2000 higher than 5 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI